The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.

The present disclosure relates to the technical field of biology, and in particular to a Macrobrachium nipponense Cathepsin L gene and use of dsRNA thereof, including the Macrobrachium nipponense Cathepsin L gene, a gene fragment and the dsRNA thereof, and use of the dsRNA in inhibiting ovary development of Macrobrachium nipponense. The Macrobrachium nipponense Cathepsin L gene is obtained at first with the full-length nucleotide sequence as shown in SEQ ID No. 1 and the amino acid sequence as shown in SEQ ID No. 2. Gene fragments with sequences of SEQ ID No. 3 and SEQ ID No. 8 are obtained by using technologies such as RNA interference, and dsRNA1 and dsRNA2 are synthesized from the two gene fragments. The synthesized dsRNA1 and dsRNA2 are injected into a pericardial cavity of a female Macrobrachium nipponense and the result shows that the dsRNA1 can effectively slow down the ovary development speed of the female Macrobrachium nipponense.

Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells.

The present disclosure relates to the technical field of biology, and in particular to a Macrobrachium nipponense Cathepsin L gene and use of dsRNA thereof, including the Macrobrachium nipponense Cathepsin L gene, a gene fragment and the dsRNA thereof, and use of the dsRNA in inhibiting ovary development of Macrobrachium nipponense. The Macrobrachium nipponense Cathepsin L gene is obtained at first with the full-length nucleotide sequence as shown in SEQ ID No. 1 and the amino acid sequence as shown in SEQ ID No. 2. Gene fragments with sequences of SEQ ID No. 3 and SEQ ID No. 8 are obtained by using technologies such as RNA interference, and dsRNA1 and dsRNA2 are synthesized from the two gene fragments. The synthesized dsRNA1 and dsRNA2 are injected into a pericardial cavity of a female Macrobrachium nipponense and the result shows that the dsRNA1 can effectively slow down the ovary development speed of the female Macrobrachium nipponense.

The present invention relates to a novel polypeptide which displays IgG cysteine protease activity, and in vivo and ex vivo uses thereof. Uses of the polypeptide include methods for the prevention or treatment of diseases and conditions mediated by IgG, and methods for the analysis of IgG.

Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.

Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.

Disclosed herein are methods for treating patients that may develop or already have pre-existing gene therapy neutralizing antibodies by administering a protease that cleaves peptide bonds present in immunoglobulins or by administering a glycosidase that cleaves carbohydrate residues present on immunoglobulins, or other similar enzymatic cleavage of immunoglobulins in vivo. Also disclosed are methods for utilizing IdeS and other immunoglobulin G-degrading enzyme polypeptides for gene therapy treatment of a disease in a patient in need thereof.